Our data strongly support the possibility that the activated Stat3 pathway could serve as a therapeutic target in cervical and possibly in endometrial cancers using a dominant-negative Stat3 mutant or small molecular inhibitors. The gene discussed is STAT3; the disease is endometrial cancer.